These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2006-006075-20 A Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia 2009-09-08 bad-data
Listed as ongoing, but also has a completion date 2006-006291-38 A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia 2010-01-22 bad-data
Ongoing 2007-002222-30 Single- and Multiple-Dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem®) in Subjects with Moderate to Severe Essential Tremor not-yet-due
Ongoing 2007-003307-13 A Phase 2a, Open-label, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects with Epileptic Seizures not-yet-due
Not reported Terminated 2014-000999-26 An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. coli... 2015-05-08 due-trials
Listed as ongoing, but also has a completion date 2014-001389-93 A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of Xyrem with an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjec... 2019-01-31 bad-data
Listed as ongoing, but also has a completion date and reported results 2014-005487-15 A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatmen... 2017-02-07 bad-data
Reported results 2014-005489-31 A Long-Term, Open-Label Safety and Maintenance of Efficacy Study of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Excessive Sleepiness in Subjects with Narcolepsy or ... 2017-12-08 due-trials
Reported results 2014-005514-31 A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP 110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatmen... 2016-12-19 due-trials
Reported results 2014-005515-16 A Six-Week, Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in the Treatment of Exc... 2016-11-11 due-trials
Ongoing 2015-003930-28 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive sleepiness Due to Obstructive Sleep Ap... not-yet-due
Ongoing 2015-003931-36 A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects with Excessive Sleepiness Due to Narcolepsy not-yet-due
Ongoing 2016-000426-20 A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy not-yet-due
Other 2016-002004-10 A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Under... not-yet-due
Other 2017-003309-16 A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pedia... not-yet-due
Trial is outside EEC 2017-004316-18 Defibrotide for Patients with Hepatic Veno-occlusive Disease (VOD): A Treatment IND Study bad-data
Ongoing 2018-001311-79 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) with an Open-label Safety Extension not-yet-due